JP2010524906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524906A5 JP2010524906A5 JP2010503549A JP2010503549A JP2010524906A5 JP 2010524906 A5 JP2010524906 A5 JP 2010524906A5 JP 2010503549 A JP2010503549 A JP 2010503549A JP 2010503549 A JP2010503549 A JP 2010503549A JP 2010524906 A5 JP2010524906 A5 JP 2010524906A5
- Authority
- JP
- Japan
- Prior art keywords
- oxidepyridin
- cyclopropylmethoxy
- carboxamide
- dichloro
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 claims 1
- 230000000095 emetic effect Effects 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0702853A FR2915100B1 (fr) | 2007-04-19 | 2007-04-19 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson |
| FR0702853 | 2007-04-19 | ||
| PCT/FR2008/000534 WO2008145841A1 (fr) | 2007-04-19 | 2008-04-16 | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010524906A JP2010524906A (ja) | 2010-07-22 |
| JP2010524906A5 true JP2010524906A5 (enExample) | 2010-11-18 |
| JP5386478B2 JP5386478B2 (ja) | 2014-01-15 |
Family
ID=38712405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503549A Expired - Fee Related JP5386478B2 (ja) | 2007-04-19 | 2008-04-16 | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 |
Country Status (33)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150087252A (ko) * | 2012-11-28 | 2015-07-29 | 사노피 | 4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도피리딘-4-일)-5-메톡시피리딘-2-카복스아미드의 결정 형태의 제조 방법 및 이의 결정 형태 |
| US9624100B2 (en) | 2014-06-12 | 2017-04-18 | Apple Inc. | Micro pick up array pivot mount with integrated strain sensing elements |
| WO2025080415A1 (en) * | 2023-10-12 | 2025-04-17 | Alto Neuroscience, Inc. | Treatment of neuropsychiatric disorders with tilivapram |
| WO2025079694A1 (ja) * | 2023-10-12 | 2025-04-17 | 株式会社 メドレックス | 経皮吸収組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
| ES2176251T3 (es) * | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| WO2001047915A1 (en) * | 1999-12-23 | 2001-07-05 | Icos Corporation | Cyclic amp-specific phosphodiesterase inhibitors |
| HUP0600103A2 (en) * | 2001-03-02 | 2006-06-28 | Bristol Myers Squibb Co | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| WO2004005258A1 (en) * | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| ES2362484T3 (es) * | 2003-03-12 | 2011-07-06 | Celgene Corporation | Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos. |
| WO2006135828A2 (en) * | 2005-06-10 | 2006-12-21 | Memory Pharmaceuticals Corporation | Trisubstituted amines as phosphodiesterase 4 inhibitors |
| US20070021451A1 (en) * | 2005-07-20 | 2007-01-25 | Hamamatsu University School Of Medicine | Method for preventing or treating neurologic damage after spinal cord injury |
-
2007
- 2007-04-19 FR FR0702853A patent/FR2915100B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-15 PA PA20088776801A patent/PA8776801A1/es unknown
- 2008-04-16 CN CN2008800126498A patent/CN101663035B/zh not_active Expired - Fee Related
- 2008-04-16 PT PT08787963T patent/PT2146714E/pt unknown
- 2008-04-16 ES ES08787963T patent/ES2367408T3/es active Active
- 2008-04-16 CA CA2684174A patent/CA2684174C/fr not_active Expired - Fee Related
- 2008-04-16 MX MX2009011284A patent/MX2009011284A/es active IP Right Grant
- 2008-04-16 EA EA200970970A patent/EA019194B1/ru not_active IP Right Cessation
- 2008-04-16 AT AT08787963T patent/ATE513548T1/de active
- 2008-04-16 JP JP2010503549A patent/JP5386478B2/ja not_active Expired - Fee Related
- 2008-04-16 DK DK08787963.1T patent/DK2146714T3/da active
- 2008-04-16 EP EP08787963A patent/EP2146714B1/fr active Active
- 2008-04-16 AU AU2008257322A patent/AU2008257322B2/en not_active Ceased
- 2008-04-16 ME MEP-2009-299A patent/ME00935B/me unknown
- 2008-04-16 BR BRPI0810444A patent/BRPI0810444A2/pt not_active IP Right Cessation
- 2008-04-16 SI SI200830357T patent/SI2146714T1/sl unknown
- 2008-04-16 KR KR1020147033000A patent/KR20150004885A/ko not_active Ceased
- 2008-04-16 HR HR20110666T patent/HRP20110666T1/hr unknown
- 2008-04-16 NZ NZ580482A patent/NZ580482A/en not_active IP Right Cessation
- 2008-04-16 WO PCT/FR2008/000534 patent/WO2008145841A1/fr not_active Ceased
- 2008-04-16 KR KR1020097021593A patent/KR101503942B1/ko not_active Expired - Fee Related
- 2008-04-16 PL PL08787963T patent/PL2146714T3/pl unknown
- 2008-04-16 MY MYPI20094343A patent/MY148092A/en unknown
- 2008-04-16 RS RS20110358A patent/RS51869B/sr unknown
- 2008-04-17 JO JO2008182A patent/JO2678B1/en active
- 2008-04-17 TW TW097113997A patent/TWI439269B/zh not_active IP Right Cessation
- 2008-04-18 AR ARP080101602A patent/AR066108A1/es unknown
- 2008-04-18 UY UY31035A patent/UY31035A1/es not_active Application Discontinuation
- 2008-04-18 CL CL2008001136A patent/CL2008001136A1/es unknown
-
2009
- 2009-10-05 US US12/573,326 patent/US20100130554A1/en not_active Abandoned
- 2009-10-11 IL IL201448A patent/IL201448A/en not_active IP Right Cessation
- 2009-10-16 ZA ZA2009/07251A patent/ZA200907251B/en unknown
- 2009-11-10 MA MA32333A patent/MA31367B1/fr unknown
-
2011
- 2011-09-15 CY CY20111100887T patent/CY1111840T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| JP2022058688A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2010522137A5 (enExample) | ||
| JP2010536849A5 (enExample) | ||
| JP2007500154A5 (enExample) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| JP2013542247A5 (enExample) | ||
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013511507A5 (enExample) | ||
| JP2021152008A5 (enExample) | ||
| JP2010518086A5 (enExample) | ||
| JP2006508953A5 (enExample) | ||
| JP2016539156A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2013516493A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2018537507A5 (enExample) | ||
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| JP2005508963A5 (enExample) | ||
| JP2009517411A5 (enExample) |